Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11

International Journal of Toxicology
Andrew LeberJosep Bassaganya-Riera

Abstract

BT-11 is an orally active, gut-restricted investigational therapeutic targeting the lanthionine synthetase C-like 2 pathway with lead indications in ulcerative colitis (UC) and Crohn disease (CD), 2 manifestations of inflammatory bowel disease (IBD). In 5 mouse models of IBD, BT-11 is effective at oral doses of 8 mg/kg. BT-11 was also efficacious at nanomolar concentrations in primary human samples from patients with UC and CD. BT-11 was tested under Good Laboratory Practice conditions in 90-day repeat-dose general toxicity studies in rats and dogs, toxicokinetics, respiratory, cardiovascular and central nervous system safety pharmacology, and genotoxicity studies. Oral BT-11 did not cause any clinical signs of toxicity, biochemical or hematological changes, or macroscopic or microscopic changes to organs in 90-day repeat-dose toxicity studies in rats and dogs at doses up to 1,000 mg/kg/d. Oral BT-11 resulted in low systemic exposure in both rats (area under the curve exposure from t = 0 to t = 8 hours [AUC0-8] of 216 h × ng/mL) and dogs (650 h × ng/mL) and rapid clearance with an average half-life of 3 hours. BT-11 did not induce changes in respiratory function, electrocardiogram parameters, or behavior with single oral doses ...Continue Reading

References

Feb 1, 1976·Mutation Research·M H Green, W J Muriel
Jun 1, 1977·Toxicology and Applied Pharmacology·P M Edwards, V H Parker
Aug 1, 1988·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·V C MoserR C MacPhail
May 1, 1973·Mutation Research·J A Heddle
Jun 1, 1974·European Journal of Pharmacology·S I Ankier
Jun 1, 1994·Mutation Research·M HayashiH Shimada
Nov 28, 2002·Experimental Animals·Hiroyasu Miyazaki, Masahiro Tagawa
Sep 27, 2006·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Amir J GuriJosep Bassaganya-Riera
Feb 1, 2004·Clinics in Colon and Rectal Surgery·Uma Mahadevan
Aug 24, 2012·Lancet·Daniel C Baumgart, William J Sandborn
Aug 24, 2012·Lancet·Ingrid OrdásWilliam J Sandborn
May 28, 2016·International Journal of Toxicology·Philippe BisselJosep Bassaganya-Riera
Mar 9, 2017·Frontiers in Immunology·Andrew LeberRaquel Hontecillas
Jun 16, 2017·Expert Review of Clinical Immunology·Julian Panés, Ignacio Alfaro
Jul 1, 2017·Frontiers in Nutrition·Elena ZocchiJosep Bassaganya-Riera
Aug 3, 2017·Artificial Intelligence in Medicine·Andrew LeberJosep Bassaganya-Riera

❮ Previous
Next ❯

Methods Mentioned

BETA
equilibrium dialysis
Assay
flow cytometry
chromosomal aberration

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.